Summary Glucocorticoid-induced TNF receptor (TNFR)-related protein (GITR) agonistic antibodies are expected to increase the antitumor response mainly by reducing the effect of Foxp3+ T-regulatory cells. TRX-518 is a novel GITR agonist that has shown good pharmacodynamic activity by depleting regulatory T cells (Tregs) in preclinical models, with limited clinical activity demonstrated in patients with advanced solid tumors. See related article by Davar et al., p. 3990

中文翻译：

---

癌症中的 GITR 抗体：尚未准备好迎接黄金时期

摘要 糖皮质激素诱导的 TNF 受体 (TNFR) 相关蛋白 (GITR) 激动性抗体预计主要通过减少 Foxp3+ T 调节细胞的作用来增强抗肿瘤反应。TRX-518 是一种新型 GITR 激动剂，在临床前模型中通过消耗调节性 T 细胞 (Treg) 显示出良好的药效活性，但在晚期实体瘤患者中表现出有限的临床活性。请参阅 Davar 等人的相关文章，第 17 页。3990